Olga Militano

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children”.

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children

New England Journal of Medicine(2024)10.1056/nejmoa2411680

N/A

3.0DataRank · unranked

188 citations

Rachel E. Rau, John A. Kairalla, Karen R. Rabin, Cindy Wang, Anne Angiolillo +28 more

Methotrexate Scarcity Among Children’s Oncology Group Institutions: Results of a Multinational Survey

The Oncologist(2023)10.1093/oncolo/oyad323

N/A

0DataRank · unranked

8 citations

Olga Militano, Andrew Ostrenga, M. Brooke Bernhardt, Brittany M. Lee, Yoram Unguru +1 more

Children's Oncology Group's 2023 blueprint for research: Pharmacy

Pediatric Blood & Cancer(2023)10.1002/pbc.30581

N/A

0DataRank · unranked

1 citations

Jennifer Thackray, Ha‐Mill H. McLearan, Kevin M. Mulieri, Elizabeth K. Bisaccia, Olga Militano +3 more

Effects of age, obesity, and body surface area on asparaginase-associated toxicities during acute lymphoblastic leukemia induction therapy: A report from the Children’s Oncology Group.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.7000

N/A

0DataRank · unranked

6 citations

Olga Militano, Zhiguo Chen, Meenakshi Devidas, Luke Maese, Rachel E. Rau +13 more

PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A children’s oncology group pediatric early-phase clinical Trial Network study.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11527

N/A

0DataRank · unranked

11 citations

Katherine A. Janeway, Charles G. Minard, David Hall, Brian D. Crompton, Alexander J. Lazar +8 more

A phase 1/2 study of bay 18953444 (Elimusertib) in pediatric patients with relapsed or refractory solid tumors: Initial report of the phase 1 results of PEPN2112.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e15131

N/A

0DataRank · unranked

9 citations

Julia Glade Bender, Charles G. Minard, Xiaowei Liu, Kristina Z. Denic, Joel M. Reid +8 more

A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: Second safety phase results from Children’s Oncology Group AALL1732.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.10016

N/A

0DataRank · unranked

20 citations

Jennifer L. McNeer, Susan R. Rheingold, Meenakshi Devidas, Zhiguo Chen, Deepa Bhojwani +12 more